Kim, T.R.; Son, B.; Lee, C.G.; Park, H.-O. Amphiregulin in Fibrotic Diseases and Cancer. Int. J. Mol. Sci. 2025, 26, 6945.

Kim, H.-Y.; Kim, T.-R.; Kim, S.-H.; Kim, I.-H.; Kim, W.-I.; Park, J.-H.; Ko, Y.; Yun, S.; Park, H.-O.; Kim, J.-C. Systemic toxicity and toxicokinetics study of self-assembled-micelle inhibitory RNA-targeting amphiregulin in cynomolgus monkeys following intravenous injection. Toxicol. Res. 2025, 41, 369–384.

Hwang, H.; Park, K.-H.; Kwon, J.-L.; Park, H.-O.; Kim, J. Analysis of self-assembled micelle inhibitory RNA (SAMiRNA) drug using ion-pairing reversed-phase liquid chromatography combined with mass spectrometry. J. Am. Soc. Mass Spectrom. 2024, 35, 1301–1309.

Son, B.; Kim, T.R.; Park, J.H.; Yun, S.I.; Choi, H.; Choi, J.W.; Jeon, C.; Park, H.O. SAMiRNA Targeting Amphiregulin Alleviate Total-Body-Irradiation-Induced Renal Fibrosis. Radiat. Res. 2022, 197, 471–479.

Yun, S.I.; Lee, S.K.; Goh, E.A.; Kwon, O.S.; Choi, W.; Kim, J.; Lee, M.S.; Choi, S.J.; Lim, S.S.; Moon, T.K.; et al. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci. Rep. 2022, 12, 1607.

Kim, H.Y.; Kim, T.R.; Kim, S.H.; Kim, I.H.; Lim, J.O.; Park, J.H.; Yun, S.; Lee, I.C.; Park, H.O.; Kim, J.C. Four-Week Repeated Intravenous Dose Toxicity of Self-Assembled-Micelle Inhibitory RNA-Targeting Amphiregulin in Mice. Int. J. Toxicol. 2021, 40, 453–465.

Kim, H.Y.; Kim, T.R.; Kim, S.H.; Kim, I.H.; Ko, Y.; Yun, S.; Lee, I.C.; Park, H.O.; Kim, J.C. Genotoxicity evaluation of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle for the treatment of fibrotic disease. Drug Chem. Toxicol. 2022, 45, 2109–2115.

Kim, T.R.; Kim, H.Y.; Kim, I.H.; Kim, K.C.; Ko, Y.; Park, J.H.; Yun, S.; Lee, I.C.; Kim, S.H.; Park, H.O. Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform. Toxicol. Rep. 2021, 8, 839–845.

Son, S.S.; Hwang, S.; Park, J.H.; Ko, Y.; Yun, S.I.; Lee, J.H.; Son, B.; Kim, T.R.; Park, H.O.; Lee, E.Y. In vivo silencing of amphiregulin by a novel effective Self-Assembled-Micelle inhibitory RNA ameliorates renal fibrosis via inhibition of EGFR signals. Sci. Rep. 2021, 11, 2191.

Yoon, P.O.; Park, J.W.; Lee, C.M.; Kim, S.H.; Kim, H.N.; Ko, Y.; Bae, S.J.; Yun, S.; Park, J.H.; Kwon, T.; et al. Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis. J. Biol. Chem. 2016, 291, 6433–6446.

Lee, C.M.; Park, J.W.; Cho, W.K.; Zhou, Y.; Han, B.; Yoon, P.O.; Chae, J.; Elias, J.A.; Lee, C.G. Modifiers of TGF-beta1 effector function as novel therapeutic targets of pulmonary fibrosis. Korean J. Intern. Med. 2014, 29, 281–290.

Zhou, Y.; Lee, J.Y.; Lee, C.M.; Cho, W.K.; Kang, M.J.; Koff, J.L.; Yoon, P.O.; Chae, J.; Park, H.O.; Elias, J.A.; et al. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-beta-induced pulmonary fibrosis. J. Biol. Chem. 2012, 287, 41991–42000.